Home MarketIpca Laboratories Ltd.

Ipca Laboratories Ltd. Stock Info: As on 2017-12-11 12:54:59

Nse

536.20

-7.05(-1.30%)
Change%
52 Week Range
400.00
11.00
657.60
5.00
Open547.00
Day's Range434.60 - 651.90
Value Traded (in ₹ Cr.) 1.15

Bse

538.05

-2.60(-0.48%)
Change %
52 Week Range
400.00
11.00
656.00
5.00
Open548.00
Day's Range432.52 - 648.78
Value Traded (in ₹ Cr.) 0.12

Stock Exchange

Category No. Of Shares Share %
ForeignPromoters 0.00 0.00%
IndianPromoters 58,216,236.00 46.13%
Mutual Funds/UTI 29,612,700.00 23.47%
FII 16,670,124.00 13.21%
Employee 0.00 0.00%
Public 13,588,130.00 10.77%
Government 0.00 0.00%
Others 5,414,850.00 4.29%
More

Key Statistics

Valuation Measures
Market Cap / Sales Ratio 2.60
Basic EPS (Rs.) 7.25
Cash EPS 20.69
BVPerShare Excl 182.73
Operating Revenue 223.13
PBDITPerShare 24.40
Dividend 0.00
NPPerShare 7.25
Current Ratio 1.82
Quick Ratio 0.82
PriceToBV 3.17
Earnings 0.01
PBDIT Margin 10.93
PBT Margin 3.85
NP Margin 3.24
Return On Assets 2.39
Retention Ratios 0.00
Parameter Mar-16 (₹ Cr.) Yoy%change
Total Income 2,838.92
Total Expenses 2,730.40
EBITDA 307.91
PBT 108.52
PAT 91.45
Net Income 91.45
More
Parameter Mar-16 (₹ Cr.) 6M % change
Total Income 1,322.34
Total Expenses 1,239.92
EBITDA -1.55
PBT 61.49
PAT 60.87
Net Income 0.00
More
Total Assets
Total Assets
Parameter Mar-16 (₹ Cr.) Yoy%change
Total share capital 25.24
Net worth 2,306.09
Investments 96.47
Total Liability 3,822.84
Total debt 595.01
Net block 2,097.02
Total Assets 3,822.84
Parameter Sep-16 (₹ Cr.) 6M % change
Total share capital 25.24
Net worth 2,247.78
Investments 142.42
Total Liability 3,862.28
Total debt 854.70
Net block 2,080.22
Total Assets 3,862.28
Company Curr Price Prev. Close Change% W's Low/High

Aarti Drugs Ltd.

553 555.75 -0.49
536.65570

Abbott India Ltd.

5610 5643.2 -0.59
5274.555659

Ajanta Pharma Ltd.

1468 1445.8 1.54
12561459.05

Albert David Ltd.

341.9 335.8 1.82
325358

Alembic Ltd.

44.65 43.75 2.06
39.444.7

Alembic Pharmaceuticals Ltd.

517.8 518 -0.04
510520

Alkem Laboratories Ltd.

2160.1 2188.05 -1.28
19732218.8
Company Curr Price Prev. Close Change% W's Low/High

Aarey Drugs & Pharmaceuticals Ltd.

59.9 57.6 3.99
5059.8

Aarti Drugs Ltd.

551 553.65 -0.48
542.1567.95

Aayush Food & Herbs Ltd.

78.35 74.65 4.96
58.974.65

Abbott India Ltd.

5600 5626.3 -0.47
5250.15645

ABL Bio-Technologies Ltd.

0.81 0.78 3.85
0.750.81

Addlife Pharma Ltd.

0.46 0 0
0.460.5

Adinath Bio-Labs Ltd.

0.3 0.31 -3.23
0.30.3
More
Parameter Mar-16(in ₹ Cr.)
Cash from operating activities 485.09
Cash from investing activities -202.90
Cash from financing activities -213.96
Net change in cash 68.23

Stock Held By Mutual Fund Schemes

Scheme Holding (%)
HDFC Mid-Cap Opportunities Fund - Regular Plan 0.99%
ICICI Prudential Long Term Equity Fund 3.79%
DSP BlackRock Micro-Cap Fund 2.14%
DSP BlackRock Small And Mid Cap Fund 2.20%
Franklin India Smaller Companies Fund 1.56%
Mirae Asset Emerging Bluechip Fund 1.78%

POWERGRID inks $100mn loan pact with AIIB

Power Grid Corporation of India, a state-owned electric utilities company, on Friday said it has signed a loan agreement with Asian Infrastructure Investment Bank (AIIB). “POWERGRID has entered into a loan agreement with Asian Infrastructure Investment Bank (AIIB) for an amount of USD 100 million for funding of “HVDC Bipole link between Western Region (Raigarh, Chhattisgarh) and Southern Region (Pugalur, Tamil Nadu) –North Trichur (Kerala) scheme-2 AC system strengthening at Pugalur end,” the company said in a filing to the Bombay Stock Exchange. Meanwhile, shares of company closed day’s trade at Rs 202.90 apiece, up 0.27 per cent, on the BSE on Friday.

08-12-2017 16:56

IL&FS Engineering secures FOA from GAIL worth Rs 216 cr

IL&FS Engineering and Construction Company on Friday said it has received Fax of Acceptance (FOA) from Gas Authority of India Limited (GAIL) for 157.8 km long 30' diameter pipeline laying works for Dobhi-Durgapur-Haldia Pipeline Section (Part B) along with 13.28 km long 12' diameter spurline under Jagdishpur Haldia/Bokaro-Dhamra Natural Gas pipeline (JHBDPL) project in Jharkhand/West Bengal states. “The total value of the contract is Rs 215.79 Crores (Excluding GST) and is to be mechanically completed in 15 months from date of FOA and additional 2 month for pre-commissioning and commissioning,” IL&FS Engineering and Construction Company said in a filing to the Bombay Stock Exchange. Meanwhile, shares of company closed day’s trade at Rs 51.10 apiece, up 1.19 per cent, on the BSE on Friday.

08-12-2017 16:42

Axis Bank reappoints Shikha Sharma as MD & CEO for 3 yrs

Private sector lender Axis Bank on Friday said that its board has reappointed Shikha Sharma as the Managing Director & CEO of the bank for a period of 3 years, w.e.f. 1st June 2018. “The Board of Directors at its meeting held on 7th December 2017, has approved the terms and conditions relating to the said re-appointment, including remuneration, in terms of the relevant provision of the Companies Act, 2013, the relevant Rules made thereunder, applicable provisions of the Banking Regulation Act, 1949 and the Guidelines issued by the RBI and the relevant provisions of the Articles of Association of the Bank, subject to approval of the RBI and the Shareholders of the Bank,” Axis Bank said in a filing to the Bombay Stock Exchange. The bank further said that Shikha Sharma shall not be liable to retire by rotation during the said period. Meanwhile, shares of bank closed day’s trade at Rs 542.45 apiece, up 1.55 per cent, on the BSE on Friday.

08-12-2017 16:41

Pledgees invoke 3.19% shares of debt laden Videocon

Debt-ridden Videocon group today said 3.19 per cent shares pledged by promoter group entities have been invoked by various pledgees, reported PTI. In a BSE filing, Videocon Industries said 1.06 crore shares or 3.19 per cent stake in company, pledged by promoter group entities Videocon Realty and Infrastructures Ltd, TekCare India India Pvt Ltd, Solitaire Appliances Pvt Ltd, Electroparts (India) Pvt Ltd were invoked. Since October 18, 2017 till November 24, 2017, total 1.06 crore shares have been invoked by various pledgees. Due to such invocation...the promoters shareholding reduced to 3.19 per cent of the paid-up share capital of the company. Promoter and promoter group entities held 58.05 per cent stake in the company. It now stands at 54.85 per cent. Last month, the Videocon group, which is reeling under a debt of over Rs 40,000 crore, sold its home appliances brand Kenstar to private equity firm Everstone Group. The Videocon group has also decided to merge its direct- to-home business to Dish TV. It had also sold its spectrum in six circles for a consideration of Rs 4,428 crore to telecom major Bharti Airtel.

08-12-2017 16:11

Unitech approaches NCLT against move to take over management

Hours after NCLT debarred its 10 directors, Unitech today approached the tribunal contending that the government had not informed the forum of SupremeCourt bar on any coercive action against the company. In a high drama at the National Company Law Tribunal (NCLT), Unitech first suffered a jolt when its 10 directors were suspended by the tribunal, which allowed government to appoint their replacements. Ramesh Chandra-led Unitech, approached the NCLT in the afternoon saying that no coercive steps for execution can be taken in view of a November 20 order of the Supreme Court. Earlier in the day, Unitech was dragged to the tribunal by the government seeking to take over the functioning of the firm alleging mismanagement and siphoning of funds by the management. Th counsel representing Unitech approached the NCLT, when the tribunal assembled post lunch hearing, contending that government has not shown the facts correctly. The tribunal would hear the matter later this afternoon. In the morning, a two-member NCLT bench headed by Chairman Justice M M Kumar also directed the government to give 10 names by December 20, the next date of hearing. The tribunal's direction came over a petition filed by the government to take over management of the company alleging mismanagement and siphoning of funds by the management. NCLT has also issued notice to Unitech Ltd directing it to file reply over it. In view of the fact and satisfaction of basic criteria for interim directions, a prima facie case is made out and in larger public interest we grant the interim directions, Justice MM Kumar said pronouncing the order. Additional Solicitor General Sanjay Jain, appearing for the government in NCLT, said: They (tribunal) have permitted the central government to appoint 10 nominee directors to run the day to day business and list of that would be given by 20th December. He further said, We want to avoid insolvency of this company, otherwise the 19,000 home buyers will be left high and dry. Moreover, there are around 51,000 depositors of Unitech. Nobody had appeared for Unitech in the morning. Jain told the tribunal that the government tried to serve Unitech an advance copy of the petition but Unitech refused to accept it and the official was not allowed enter Unitech's office. According to Jain, the NCLT has also directed that the suspended directors of the company shall not sell, mortgage or create charge either their properties or company's properties. In April this year, the Economic Offence Wing (EOW) of the Delhi Police arrested Unitech Ltd's Managing Director Sanjay Chandra and his brother Ajay Chandra for allegedly not developing a project despite receiving funds from investors. The company has over Rs 6,000 crore debt with more than 16,000 undelivered units from a total of nearly 70 projects.

08-12-2017 15:52

Ipca Laboratorie - Updates

IPCA Laboratories Limited has informed the Exchange regarding ''Half yearly certificate under Regulation 52(5) of the SEBI (LODR) Regulations, 2015, for Debt Securities''.

15-Nov-2017 05:18 PM

Ipca Laboratorie - Updates

Pursuant to Regulation 52(5) of the SEBI (LODR) Regulations, 2015, we are enclosing herewith a certificate issued by M/s. IDBI Trusteeship Services Ltd. (Debenture Trustees) for the half year ended September 30, 2017 in respect of the Non Convertible Debentures issued by the Company.

15-Nov-2017 05:06 PM

Ipca Laboratorie - Financial Result Updates

IPCA Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2017.

15-Nov-2017 09:34 AM

Ipca Laboratorie Q2 net profit jumps 75.56% at Rs 96.47 cr

The company reported standalone net profit of Rs 96.47 crore for the quarter ended September 30, 2017 as compared to Rs 54.95 crore in the same period last year, registering a year-on-yeargrowthof 75.56 per cent. Net revenue of the company rose marginally by 1.34 per cent at Rs 864.29 crore in July-September quarter of this fiscal as against Rs 852.90 crore in the corresponding period last year. During July-September quarter, operating expenses dropped by 3.86 per cent to Rs 715.26 crore from Rs 744.00 crore in year ago period. Other Income grew by 77.71 per cent at Rs 11.00 crore versus (Sep'16 Rs 6.19 crore). Operating Profit surged by 16.40 per cent to Rs 149.03 crore as against Rs 128.03 crore in the year ago period, while Operating Profit Margin (OPM) expanded year-on-year to 14.86 per cent in September quarter. Interest grew by 708.57 per cent y-o-y to Rs 6.39 crore, while Taxation decreased by 64.92 per cent at Rs 13.12 crore (Sep'16 Rs 37.40 crore).

14-Nov-2017 03:01 PM

Ipca Laboratorie - Outcome of Board Meeting

Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, we enclose herewith our Standalone Unaudited Financial Results along with limited review report of the Company's Auditors for the 2nd Quarter and half year ended 30th September, 2017 of the financial year 2017-18, which was taken on record at the Meeting of the Board of Directors of the Company held today at Mumbai.

14-Nov-2017 01:06 PM

Ipca Laboratorie - Updates

Pursuant to Regulation 52(5) of the SEBI (LODR) Regulations, 2015, we are enclosing herewith a certificate issued by M/s. IDBI Trusteeship Services Ltd. (Debenture Trustees) for the half year ended September 30, 2017 in respect of the Non Convertible Debentures issued by the Company.

15-Nov-2017 05:06 PM

Ipca Laboratorie - Outcome of Board Meeting

Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, we enclose herewith our Standalone Unaudited Financial Results along with limited review report of the Company's Auditors for the 2nd Quarter and half year ended 30th September, 2017 of the financial year 2017-18, which was taken on record at the Meeting of the Board of Directors of the Company held today at Mumbai.

14-Nov-2017 01:06 PM

Ipca Laboratorie - Outcome of Board Meeting

Pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, we enclose herewith our Standalone Unaudited Financial Results along with limited review report of the Company's Auditors for the 2nd Quarter and half year ended 30th September, 2017 of the financial year 2017-18, which was taken on record at the Meeting of the Board of Directors of the Company held today at Mumbai.

14-Nov-2017 01:05 PM

Corporate Details

About Management

One of the first modern pharma factory of yesteryears was commissioned by Ipca at Mumbai in 1969. The company was originally promoted by a group of medical professionals and businessmen and was incorporated as 'The Indian Pharmaceutical Combine Association Limited.' in October 1949. The present management took over in November 1975 when the total turnover of the company was just Rs. 0.54 crores. Currently, this premise where Ipca started its operations, houses the Registered Office of the company. Key departments like International Marketing, R&D (Formulations) and Analytical Development Lab are located here. YEAR EVENTS 1949 - Ipca Laboratories Ltd. was incorporated on 19th October, in Mumbai, under the name `The Indian Pharmaceutical Combine Association Limited'. The Company manufacture pharmaceutical products such as tablets, capsules, vials and ampoules. The Company was promoted by a group of medical professionals viz., Dr. N.K. Chaina, Dr. A.M. Desai, Dr. N.S. Tibrawala, K.M. Shroff, S.F. Kirawal, U.H. Dalal and K.B. Mehla. 1964 - The name was subsequently changed to `Ipca Laboratories Ltd.' on 6th August 1964. The name was further changed to `Ipca Laboratories Private Limited' on 13th January 1966. The name of the company was again changed to `Ipca Laboratories Ltd.' on 9th August 1988. The company became a Public Limited Company on 24th March, 1993. 1975 - The management of the company was taken over by Amitabh Bachchan, Ajitabh Bachchan, Jaya Bachchan, M.R. Chandurkar, P.C. Godha. 1994 - The Company undertook to set up a modern plant at Athal, Silvassa, for manufacture of pharmaceutical formulations. Plant and machinery comprising blenders, auto tablet coaters, fluid bed dryers, etc., procured indigenously. The Tatlam bulk drug unit capacity was increased to 500 TPA. 1995 - 9,225,000 No. of equity shares allotted to promoters, friends, relatives and associates (of these, 225,000 were Rights shares at a premium of Rs 120 per share). During February, the Company issued 3,275,000 No. of equity shares of Rs 10 each at a premium of Rs 120 per share of which 150,000 shares reserved for allotment on a preferential basis to employees of the Company (all were taken up). Balance 3,125,000 shares issued to the public (all were taken up). 2002-R S Hugar, former managing director of Global Trust Bank, has joined the board of directors of Ipca as non-executive chairman with effect from June 11, 2002. 2003 -Launched new domestic marketing division, ACTIVA , dedicated to Rheumatology Care. First Company in India to have such division for marketing superspeciality molecules. - Launched new domestic marketing division,Hy Care dedicated to Cardio-Diabetology segments. - Wholly owned subsidiary `Ipca Pharmaceuticals Inc.' incorporated in United States of America. -Wholly owned subsidiary `Ipca Laboratories (UK) Ltd.' incorporated in United Kingdom. - Forbes, a leading US business magazine, selected among its top 200 successful, rising companies outside USA, with sales under USD 1 Billion. 2004 -Members of the Company have approved the amalgamation in the nature of merger of Innotech Pharma Ltd., a 100% subsidiary of the Company, with Company -Ipca Laboratories Ltd. unveils novel injectable antibiotic combination of cefotaxime sodium with sulbactam sodium for the first time in the country under the brand name 'Sultax' -Received 'Lifetime Achievement Award' for the year2002-03 from from CHEMEXIL (Basic Chemicals,Pharmaceuticals & Cosmetics Export Promotion Council)for export promotion over the years. -Commissioned new formulation plant at Silvassa -Forbes Asia, a leading US business magazine selected Ipca, for the second consecutive year as one among the first 200 'Best under a Billion Company' in Asia 2005 -Ipca Laboratories Ltd has informed that the Company has entered into a Joint Venture (JV) agreement with Chongqing Holley Holding Company Ltd of China. -Merger of Innotech Pharma Limited with Ipca Laboratories Limited in August, 2005. -Acquires Cardiac brand ISORDIL from Wyeth Limited. -Forbes Asia, a leading US business magazine selected Ipca, for the third consecutive year as one among the first 200 'Best under a Billion Company' in Asia. - Ipca Laboratories has given the Bonus in the Ratio of 1:1 2006 -Ipca Laboratories Enters into Strategic Alliance with Ranbaxy Pharmaceuticals Inc., for the US Market -Ipca Laboratories launches fixed dose ACT combination and stops manufacturing of single ingredient Oral Artemisinin derivatives. -Ipca's new plant at Dehradun commenced operation on 5th May, 2006 2007 -Ipca - Ranbaxy Alliance received U.S. FDA marketing approval for Atenolol Tablets -Ipca Laboratories granted US FDA approval for Hydroxychloroquine sulfate tablet -Ipca Laboratories - Acquisition of 100% shareholding of formulation dossier registration holding companies in Australia and N -Ipca launched eighth domestic marketing division, 'Altus' which caters to intensivists and surgeons. -Ipca has been awarded by Forbes Inc., as one of the 'Best under a Billion' Forbes Global's 200 Best Small Companies, 2007. In the past, company has received same award for three consecutive years' 2003, 2004 and 2005. 2008 -Ipca Laboratories receives US FDA approval for Propranolol Hydrochloride Tablets -Tonira Pharma's Nandesari unit (API plant at Baroda) receives US-FDA approval. -Ipca Laboratories Ltd has re-appointed Mr. Premchand Godha as the Managing Director of the Company for a further period of 5 years w.e.f. April 01, 2008. -Ipca-Piparia, formulation manufacturing unit receives MHRA-UK approval. This is the 3rd plant after Athal and Kandla receiving this qualification. -WHO prequalify Ipca's dossier of ARTESUNATE + AMODIAQUINE Co Blister making Ipca the 2nd company in the world and the first Indian company to receive this prequalification. 2009 -Ipca received Best Patent Award during the year 2007 - 08 2010 - Ipca Laboratories Ltd has informed that the Board of Directors of the Company at its meeting held on January 21, 2010, inter alia, appointed Mr. Anand T Kusre as a Director of the Company. -Company has splits its Face value of Shares from Rs 10 to Rs 2 2011 -Ipca Laboratories has received approval from UK Medicines and Healthcare Products Regulatory Agency for its fourth manufacturing unit at a Special Economic Zone in Indore for good manufacturing practices under the regulator. -Ipca labs bags nod to amalgamate Tonira Pharma 2012 -Mr. Dev Parkash Yadava has been appointed as an Additional Director of the Company -IPCA Laboratories bags USFDA nod Indore formulations manufacturing facility 2013 -IPCA received Corporate Citizen Award' for best corporate governance practice. -IPCA Dehradun won the "Energy Conservation" Award for the 3rd year in a row. -IPCA featured on the 8th position in the list of 'India's Most Admired Companies, in a survey carried out by Fortune India, in collaboration with The Hay Group, for the second time. -IPCA Laboratories said that SEZ Indore formulations manufacturing unit has been found acceptable after the inspection of US-FDA. 2014 -IPCA Laboratories "Acquisition of High Potency Oral Solid Dosage formulations manufacturing unit situated at Pithampur near Indore". -IPCA has entered into an alliance with Oncobiologics, Inc. USA for the development, manufacture and commercialization of biosimilar monoclonal antibody products. -IPCA Sports Club wins the E-Merck Inter-Pharma Cricket Tournament. -IPCA acquires formulations manufacturing unit located at Tarapur, Dist. Palghar, Maharashtra. -IPCA Sports Club wins Dreamz Trophy (T-20 & 40-overs format). -New product Launch - Pacimolr Active -Whistle Blower Policy implemented. 2016 -Ipca Lab wins Clinical and Research Excellence (CARE) awards. -Ipca was awarded by 'Indian Drug Manufacturers Association (IDMA) Best Formulation Patent (2014-15)' for its formulation patent of Hydroxychloroquine and its combinations in treatment of Diabetes Mellitus at 54th IDMA annual day celebration held on 23rd January 2016. -Ipca Laboratories wins the 'Clinical Trial result of the year' at the first annual CARE Award held at Boston, USA on 27th April 2016. -Ipca's Ratlam manufacturing Unit won 1st prize in National Energy Conservation Award 2016. This ceremony was hosted in Delhi on 14th December 2016. -Ipca Laboratories has been conferred with "Intellectual Property (IP) Excellence Award 2016" for adopting "The Best Practices in IP Intelligence" in a function organized in Mumbai on November 28th, 2016.

Registered Office

Village Ranu, (Taluka Padra),

2662-227300,,,      ,

Registrar Details

Link Intime India Pvt. Ltd.